Exclusive: After Amgen exit, father-son duo gets Lightspeed backing to fund remaining Teneobio ‘babies’

The father-son duo behind Teneobio is back with another biotech, comprising three bispecific antibodies that neither Amgen wanted when dishing out $900 million upfront last year, nor AbbVie wanted when acquiring a multiple myeloma asset in 2019.

Technically, Ancora Biotech is three shell companies, one for each of its...

Click to view original post